Low-dose DOX-polygodial nanosystem modulates the CD47/CALR axis for safer triple negative breast cancer treatment

Area of Science:

• Oncology
• Immunology
• Nanotechnology

Background:

• Triple Negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer.
• Immunosurveillance plays a critical role in TNBC progression, drug resistance, and metastasis.
• Cluster of Differentiation 47 (CD47) and calreticulin (CALR) are key regulators of immunosurveillance.

Purpose of the Study:

• To examine CD47 and CALR mRNA expression in breast cancer tissues compared to normal tissues.
• To investigate the role of CD47 and CALR in chemoresistance at sublethal drug doses.
• To evaluate the effect of combination therapy (doxorubicin + polygodial) and nanoparticle delivery on CD47 and CALR expression.

Main Methods:

• Analysis of CD47 and CALR mRNA expression in patient tissues.
• MTT assay to determine sublethal drug concentrations for MDA-MB-231 cells.
• Treatment of cells with doxorubicin (DOX), polygodial (PG), or both.
• Synthesis and characterization of Hyaluronic Acid (HA)-grafted chitosan nanoparticles (NPs) loaded with DOX/PG.
• Analysis of CD47/CALR expression following treatment and NP delivery.

Main Results:

• Combination treatment (DOX + PG) significantly decreased CD47 and CALR levels.
• Co-loaded NPs with DOX/PG also significantly reduced CD47 and CALR expression.
• The combination therapy reversed the elevated CD47 and CALR levels observed in cancer tissues.
• Treatment enhanced the calreticulin (CALR) to Cluster of Differentiation 47 (CD47) surface expression ratio.

Conclusions:

• Combination therapy with doxorubicin and polygodial, particularly when delivered via HA-grafted chitosan nanoparticles, shows promise in modulating immunosurveillance markers in TNBC.
• This strategy may offer a novel approach for metastasis inhibition and maintenance therapy in aggressive breast cancer.
• Further in vivo studies and dose optimization are warranted to validate these findings.